CRL Charles River
- 192.900
- -1.180-0.61%
- 192.900
- 0.0000.00%
Charles River News
BofA Securities Downgrades Charles River(CRL.US) to Hold Rating, Cuts Target Price to $215
BofA Securities Downgrades Charles River(CRL.US) to Hold Rating, Cuts Target Price to $215
Charles River Downgraded to Neutral From Buy at BofA
Bio-Rad Upped by Citi to Buy; Charles River, Hologic Downgraded
Charles River Analyst Ratings
Citi Downgrades Charles River(CRL.US) to Sell Rating, Cuts Target Price to $175
Evercore Maintains Charles River(CRL.US) With Buy Rating, Maintains Target Price $225
Evercore ISI Sticks to Their Buy Rating for Charles River Labs (CRL)
Charles River Labs Is Maintained at Neutral by Baird
Charles River Analyst Ratings
Mizuho Securities Maintains Charles River(CRL.US) With Hold Rating, Announces Target Price $210
Mizuho Securities Maintains Charles River(CRL.US) With Hold Rating
Hold Rating on Charles River Labs Amidst Pharma Restructuring and Uncertain Near-Term Earnings
Mizuho Adjusts Price Target on Charles River Laboratories International to $210 From $235, Maintains Neutral Rating
Charles River Analyst Ratings
Analysts Offer Insights on Healthcare Companies: AnaptysBio (ANAB), Charles River Labs (CRL) and Akero Therapeutics (AKRO)
Charles River Analyst Ratings
Baird Cuts Charles River Labs to Neutral, Cites Lagging Recovery
Morgan Stanley Cuts Price Target on Charles River Laboratories International to $215 From $235
Analysts Offer Insights on Healthcare Companies: Outset Medical (OM), Rani Therapeutics Holdings (RANI) and Charles River Labs (CRL)
Analysis
Price Target
No Data
No Data
